Skip to main content
Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help

Dr. John Cush RheumNow

3 years 9 months ago
Visit our podcast channel and listen to experts from the #SLEEducatorsNetwork discuss how biologic therapies could help address key unmet needs in #lupus, and how clinicians can identify the most appropriate patients for biologics. #SponsoredbyGSKUSMA https://t.co/zYB48YvNDC https://t.co/gL67G5jQv8
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx i

Dr. John Cush RheumNow

3 years 9 months ago
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/zFsPUdo4Wb https://t.co/rEN4yfoP9h
Frailty in Vasculitis
Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust

Dr. John Cush RheumNow

3 years 9 months ago
Sparks editorial -- RA pathogenesis has been linked to pollution, Lung Dz, smoking, silica dust, asbestos, textile dust, brick/concrete laying, pesticides, military burn pits - some w/ strong associ w/ HLA-SE and ACPA, but not ACPA-negative RA https://t.co/ZStmF8MeLD https://t.co/xQxJ74aQ81
SLE: Variability in Racial Disparities in Pregnancy Outcomes

Significant disparities exist in pregnancy outcomes in wo

Dr. John Cush RheumNow

3 years 9 months ago
SLE: Variability in Racial Disparities in Pregnancy Outcomes Significant disparities exist in pregnancy outcomes in women with SLE, w/previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women w/SLE. https://t.co/1PrJYpMcHx https://t.co/YN7K0Gf5Jl
Tapering Methotrexate with Biologics or JAK Inhibitors in RA

Dr Segan ( @JulianSegan) discusses Abstract 0916 at #ACR2

Dr. John Cush RheumNow

3 years 9 months ago
Tapering Methotrexate with Biologics or JAK Inhibitors in RA Dr Segan ( @JulianSegan) discusses Abstract 0916 at #ACR22. https://t.co/CUjZ7SiSoE https://t.co/VYtmCIJEt6
The Top 10 Research Priorities in Psoriatic Arthritis

A survey of 317 carers and clinicians focused on psoriatic arthr

Dr. John Cush RheumNow

3 years 9 months ago
The Top 10 Research Priorities in Psoriatic Arthritis A survey of 317 carers and clinicians focused on psoriatic arthritis has set an agenda of the top 10 research questions for psoriatic arthritis (PsA). https://t.co/zfivHvtLX9 https://t.co/LZsiE417w2
Systematic review comparing MIS-C and Kawasaki: 14 studies, 2928 pts; major differences- KD pts were younger; MIS-C had

Dr. John Cush RheumNow

3 years 9 months ago
Systematic review comparing MIS-C and Kawasaki: 14 studies, 2928 pts; major differences- KD pts were younger; MIS-C had more Pulm, GI, Shock, more cardiac (LV, valvular pericarditis, myocarditis), but less coronary lesions & conjunctivitis https://t.co/bcCRh5HxL7 https://t.co/qLvfCYwx9u
Comparing Biosimilar Growth in the US, Germany, and Switzerland

The biosimilar landscape will change dramatically in 2

Dr. John Cush RheumNow

3 years 9 months ago
Comparing Biosimilar Growth in the US, Germany, and Switzerland The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. https://t.co/LYcG0BNO6C https://t.co/V2m8HoIWLF
Xeljanz Cancer Risks Detailed
  • MedPage Today
The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study.
Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.
GCA: What we feel and what we can't

Dr. David Liew ( @drdavidliew) discusses Abstracts 0483 and 0486 at #ACR22 Converg

Dr. John Cush RheumNow

3 years 9 months ago
GCA: What we feel and what we can't Dr. David Liew ( @drdavidliew) discusses Abstracts 0483 and 0486 at #ACR22 Convergence. https://t.co/Pobsb2anLa https://t.co/RQS4N3TqgK
Timely Fetal Screening Important in Positive Anti-Ro Antibody Pregnancies

Dr. Yusof ( @Yuz6Yusof) discusses Abstract 0

Dr. John Cush RheumNow

3 years 9 months ago
Timely Fetal Screening Important in Positive Anti-Ro Antibody Pregnancies Dr. Yusof ( @Yuz6Yusof) discusses Abstract 0957 presented at #ACR22. https://t.co/yl4K7jZMGr https://t.co/6733AEhRyX
×